info@synapsdx.com
Facebook-f
Linkedin-in
Instagram
Menu
FOR PATIENTS
FOR PROVIDERS
ABOUT US
CONTACT US
NEWS
DISCERN™ Morphometric Imaging Assay for Alzheimer’s Disease Accurately informs diagnosis of Alzheimer’s Disease in early dementia, even in the presence of Mixed dementia
Download
Synaps Dx
Supporting Payer Treatment Reimbursement Decisions for Alzheimer’s Disease: DISCERN™ Test Provides Definitive Diagnosis of Alzheimer’s Disease and Degenerative Pathologies vs. Other Forms of Dementia
Prev post
DISCERN™ PKCƐ Assay for Alzheimer’s Disease Measuring synaptic dysfunction to inform a highly accurate diagnose Alzheimer’s Dementia in early dementia.
Next post
Search for:
Recent Posts
The Burden of Diagnosis: How physicians confront diagnosing Alzheimer’s disease with influx of patients seeking disease modifying therapies
FDA Approval of New Drug for Alzheimer’s Disease Underscores Need for DISCERN™ Accurate Diagnostic Testing Prior to Prescribing LEQEMBI™ and Finalizing Coverage
Honoring Caregivers, Patients and Families During Caregivers and Alzheimer’s Awareness Month
SYNAPS Dx Publishes First Autopsy-Confirmed Results for Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies Using DISCERN™ Test
Spotlighting Accurate, Early Diagnosis of Alzheimer’s Disease: World Alzheimer’s Month
Recent Comments
Archives
January 2023
November 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
March 2022
February 2022
January 2022
December 2021
November 2021
October 2021
October 2019
September 2019
December 2018
November 2018
Categories
Uncategorized
Meta
Log in
Entries feed
Comments feed
WordPress.org
Input your search keywords and press Enter.
Recent Comments